Evaluation of the safety of 6-weeks&apos; administration of asenapine sublingual tablets in patientｓ with schizophrenia, based on proper use in routine medical practice

Sayaka AISO

4:40 PM - 4:48 PM

[CNP-P15-1] Evaluation of the safety of 6-weeks' administration of asenapine sublingual tablets in patientｓ with schizophrenia, based on proper use in routine medical practice

^○Sayaka AISO¹, Sakura SONEHARA², Saori KAWAMATA², Shuichi HIRAOKA¹, Ryosuke HARA², Yasuhiro IWAMA³, Katsuyoshi SUZUKI², Daisuke MATSUI² (1. Meiji Seika Pharma Co.,Ltd. Medical Science Sect., 2. Meiji Seika Pharma Co.,Ltd. Safety Vigilance & Management Dept., 3. Meiji Seika Pharma Co.,Ltd. Regulatory Affairs ＆ Clinical Data Science Dept.)

Abstract password authentication.
Password to browse/download the abstracts has been sent to pre-registrants by email and printed on name badge. It is also indicated in the abstract booklet.

Presentation information

[CNP_P15] Poster Session 15

[CNP-P15-1] Evaluation of the safety of 6-weeks' administration of asenapine sublingual tablets in patientｓ with schizophrenia, based on proper use in routine medical practice

Password